ACLARIS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On January 11, 2023, management of Aclaris Therapeutics, Inc. (the "Company") will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference and at one-on-one investor meetings. The presentation will include a slide presentation. A copy of this slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number                              Exhibit Description
  99.1       Company Presentation  .
  104      The cover page from Aclaris Therapeutics, Inc.'s Form 8-K filed on
           January 9, 2023, formatted in Inline XBRL.


                                       2

© Edgar Online, source Glimpses